Clinical trial to evaluate the efficacy and safety of the fixed dose combination of Tramadol 50 mg IR + Diclofenac 75 mg SR vs fixed dose combination of Tramadol 37.5 mg + Paracetamol 325 mg in treatment of patients with moderate to severe pain due to acute musculoskeletal conditions , acute flare of osteoarthritis , acute flare of rheumatoid arthritis and post operative pai
- Registration Number
- CTRI/2011/091/000150
- Lead Sponsor
- Abbott Healthcare Private Limited, Mumbai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 200
1.Males and females aged above 18 years and less than 70 years (women of childbearing potential must have a negative pregnancy test, be non-lactating, and willing to use adequate and reliable contraception (defined as IUD, contraceptive pill or depot gestagen) throughout the study).
2.Clinical diagnosis of acute musculoskeletal pain (tendinitis, Bursitis, synovitis) acute flare of osteoarthritis, acute flare of Rheumatoid arthritis and post operative pain
3.Subjects with moderate pain confirmed by a VAS Score > 50 mm in the scale during the last 5 days prior to the Baseline Visit. (In post operative pain only those subjects will be screened who can take oral medications)
4.Subjects must be willing to discontinue all other analgesics / existing analgesic treatment.
5.Subjects willing to give informed consent.
6.Subjects willing to fill patient diary cards/ patient assessment forms and comply with the study procedure and requirements.
1.Pregnant and nursing women
2.Patients hypersensitive to Tramadol, Diclofenac and paracetamol .
3.Subjects previously discontinued from tramadol, diclofenac and paracetamol therapy due to adverse effects
4.Subjects had undergone therapy with Tramadol within 30 days before study entry.
5.Subjects had received antidepressants therapy within 4 weeks of study entry.
6.Subjects diagnosed with fibromyalgia, active peptic ulcer , GI tract bleeding.
7.Subjects also with the history of peptic ulcers, gastric irritations and NSAIDs intolerance
8.Subjects with abnormal renal and liver function parameters
9.Subjects treated with high-potent opioid analgesics (e.g. morphine, fentanyl, oxycodone, methadone, hydromorphone, ketobemidone, buprenorphine for the pain.
10.Ancillary physiotherapy massage or physical therapy within 48 hours.
11.Subjects had acupuncture within 3 weeks of study entry.
12.Subjects treated with intra- articular injection of corticosteroids within two months.
13.History of chronic condition(s) (expect OA & RA) , requiring frequent analgesic therapy (e.g. frequent headaches, frequent migraine, gout) and severe respiratory disease.
14.Subjects with history of abnormal / impaired creatinine clearance .
15.Substance or alcohol abuse, or subjects who, in the opinion of the Investigator, have demonstrated addictive or substance abuse behavior.
16.Untreated depression or other psychiatric disorder in such a way that participation in the study may, in the opinion of the Investigator, pose an unacceptable risk to the subject.
17.Subject with a history of attempted suicide or substance abuse.
18.Subjects, who are unsuitable for any other reason to participate in the study in the opinion of the Investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Reduction in pain intensity from baseline to all visits.<br>2. Pain relief at the end of the study<br>Timepoint: Baseline, Day 3 and Day 5
- Secondary Outcome Measures
Name Time Method 1. Disability score measurement from baseline to all visits<br>2. Reduction in swelling and inflammation from baseline to all the visits<br>3. Use of rescue medication <br>4. Safety parameters<br>5. Global assessment for efficacy and tolerability<br>Timepoint: Baseline, Day 3 and Day 5